Pneumococcal polysaccharide vaccine

Short description: Pneumonia vaccine

Pneumococcal polysaccharide vaccine

Vaccine description
Target disease| 23 serotypes of Streptococcus pneumoniae
Type| polysaccharide
Clinical data
Trade names| Pneumovax 23
Other names| PPSV, PPV-23, PPSV23
AHFS/Drugs.com| Monograph
MedlinePlus| a607022
License data|

* US DailyMed: vaccine polyvalent Pneumococcal vaccine polyvalent

Pregnancy
category|

* AU: B2[1]

Routes of
administration| Intramuscular
ATC code|

* J07AL01 (WHO)

Legal status
Legal status|

* US: ℞-only [2][3]

Identifiers
ChemSpider|

* none

KEGG|

* D08776

NY (what is this?) (verify)

Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides.[2] It is given by intramuscular or subcutaneous injection.[2]

The polysaccharide antigens were used to induce type-specific antibodies that enhanced opsonization, phagocytosis, and killing of Streptococcus pneumoniae (pneumococcal) bacteria by phagocytic immune cells. The pneumococcal polysaccharide vaccine is widely used in high-risk adults.[4]

First used in 1945, the tetravalent vaccine was not widely distributed, since its deployment coincided with the discovery of penicillin.[5] In the 1970s, Robert Austrian championed the manufacture and distribution of a 14-valent pneumococcal polysaccharide vaccine.[6][7] This evolved in 1983 to a 23-valent formulation (PPSV23). A significant breakthrough affecting the burden of pneumococcal disease was the licensing of a protein conjugate heptavalent vaccine (PCV7) beginning in February 2000.[8]

## Contents

* 1 Medical uses
* 2 Adverse events
* 3 Vaccination schedule
* 3.1 Adults and children over two years of age
* 3.2 Young children
* 4 References
* 5 Further reading
* 6 External links

## Medical uses

In the United States, pneumococcal vaccine, polyvalent is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).[3][2] It is approved for use in people 50 years of age or older and people aged two years of age or older who are at increased risk for pneumococcal disease.[2][9] The World Health Organization (WHO) recommendations are similar. The WHO does not recommend use of pneumococcal polysaccharide vaccine in routine childhood immunization programs.[10][11] The recommendations in the UK are similar, but include people with occupational hazards.[12]

Pneumococcal vaccine may be beneficial to control exacerbations of chronic obstructive pulmonary disease (COPD).[13]

The pneumococcal polysaccharide vaccine is important for those with HIV/AIDS. In Canadian patients infected with HIV, the vaccine has been reported to decrease the incidence of invasive pneumococcal disease from 768 per 100,000 person–years to 244 per 100,000 patient–years.[4] Because of the low level of evidence for benefit, 2008 WHO guidelines do not recommend routine immunization with PPV-23 for HIV patients, and suggests preventing pneumococcal disease indirectly with trimethoprim–sulfamethoxazole chemoprophylaxis and antiretrovirals.[10] While the U.S. Centers for Disease Control and Prevention (CDC) recommends immunization in all patients infected with HIV.[14]

## Adverse events

The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).[2]

## Vaccination schedule

### Adults and children over two years of age

The 23-valent vaccine (for example, Pneumovax 23) is effective against 23 different pneumococcal capsular types (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F), and so covers 90 percent of the types found in pneumococcal bloodstream infections.[2]

### Young children

Children under the age of two years fail to mount an adequate response to the 23-valent adult vaccine, and instead a 13-valent pneumococcal conjugated vaccine (PCV13; for example, Prevnar 13) is used instead. PCV13 replaced PCV7, adding six new serotypes to the vaccine. While this covers only thirteen strains out of more than ninety strains, these thirteen strains caused 80–90 percent of cases of severe pneumococcal disease in the U.S. before introduction of the vaccine, and it is considered to be nearly 100 percent effective against these strains.[15]

Special risk-groups
Children at special risk (e.g., sickle cell disease and those without a functioning spleen) require additional protection using the PCV13, with the more extensive PPSV-23 given after the second year of life or two months after the PCV13 dose:
Vaccination schedule for children at special risk in the UK[16] Age | 2–6 months | 7–11 months | 12–23 months

|
|
|

PCV13 | 3 × monthly dose | 2 × monthly dose | 2 doses, 2 months apart
Further dose in second year of life
PPSV-23 | Single dose after second year of life, 2 months after PCV13

## References

1. ↑ "Pneumococcal 23-polyvalent vaccine (Pneumovax 23) Use During Pregnancy". 7 October 2019. https://www.drugs.com/pregnancy/pneumococcal-23-polyvalent-vaccine.html.
2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Pneumovax 23- pneumococcal vaccine polyvalent injection, solution". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb362a20-6d91-4ae8-bebb-9ee8b2591814.
3. ↑ 3.0 3.1 "Pneumovax 23 - Pneumococcal Vaccine, Polyvalent". 28 October 2021. https://www.fda.gov/vaccines-blood-biologics/vaccines/pneumovax-23-pneumococcal-vaccine-polyvalent. This article incorporates text from this source, which is in the public domain.
4. ↑ 4.0 4.1 "The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study". BMC Infectious Diseases 11: 314. November 2011. doi:10.1186/1471-2334-11-314. PMID 22078162.
5. ↑ "Prevention of Pneumococcal Pneumonia by Immunization with Specific Capsular Polysaccharides". The Journal of Experimental Medicine 82 (6): 445–465. November 1945. doi:10.1084/jem.82.6.445. PMID 19871511.
6. ↑ "Prevention of pneumococcal pneumonia by vaccination". Transactions of the Association of American Physicians 89: 184–194. 1976. PMID 14433.
7. ↑ "Robert Austrian: 1917-2007". Clin Infect Dis 45: 2–3. 2007. doi:10.1086/520068.
8. ↑ "Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children". Vaccine 25 (45): 7858–7865. November 2007. doi:10.1016/j.vaccine.2007.08.022. PMID 17931753.
9. ↑ "Pneumococcal Vaccination - What You Should Know". 6 December 2017. https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html.
10. ↑ 10.0 10.1 "23-valent pneumococcal polysaccharide vaccine : WHO position paper". Wkly. Epidemiol. Rec. 83 (42): 373–84. 2008. PMID 18927997.
11. ↑ "World Health Organization. Pneumococcal vaccines". https://www.who.int/vaccines/en/pneumococcus.shtml.
12. ↑ "Who should have the pneumococcal vaccine?". NHS. 2019. https://www.nhs.uk/conditions/vaccinations/when-is-pneumococcal-vaccine-needed/.
13. ↑ "Pneumococcal vaccination and chronic respiratory diseases". Int J Chron Obstruct Pulmon Dis 12: 3457–3468. 2017. doi:10.2147/COPD.S140378. PMID 29255353.
14. ↑ "Pneumococcal Vaccine Timing for Adults". 16 March 2020. https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf.
15. ↑ Childhood Pneumococcal Disease – information on the disease and the Prevnar vaccine, from the Victoria State (Australia) government. [|permanent dead link|dead link}}]
16. ↑ "Pneumococcal: the green book, chapter 25". Immunisation against infectious disease. Public Health England. 2013. Gateway 2017624. https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25.

## Further reading

* "Vaccines for preventing pneumococcal infection in adults". Cochrane Database Syst Rev 1 (1): CD000422. 2013. doi:10.1002/14651858.CD000422.pub3. PMID 23440780.
* The immunological basis for immunization series: module 12: pneumococcal vaccines. World Health Organization (WHO). September 2009. ISBN 9789241598217.
* "Chapter 25: Pneumococcal". Immunisation against infectious disease. Public Health England. January 2018. https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25.
* "Chapter 17: Pneumococcal Disease". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC). 2015. ISBN 978-0990449119. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.
* "Chapter 11: Pneumococcal". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: Centers for Disease Control and Prevention (CDC). 9 January 2020. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html.
* "23-valent pneumococcal polysaccharide vaccine : WHO position paper". Wkly. Epidemiol. Rec. 83 (42): 373–84. 2008. PMID 18927997.

## External links

* Pneumococcal Disease World Health Organization (WHO)
* "Pneumococcal Polysaccharide Vaccine Information Statement". October 2019. https://www.cdc.gov/vaccines/hcp/vis/vis-statements/ppv.html.

* v
* t
* e

Artificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Biology:Inoculat, Inoculation (J07)

Development|

* Adjuvants
* List of vaccine ingredients
* Mathematical modelling
* Timeline
* Trials

Classes|

* Conjugate vaccine
* DNA vaccination
* Inactivated vaccine
* Live vector vaccine
* Attenuated vaccine
* Heterologous vaccine
* Subunit/component / Peptide / Virus-like particle
* Toxoid

Administration|

* Global:
* GAVI Alliance
* Policy
* Schedule
* Vaccine injury
* USA:
* ACIP
* Vaccine court
* Vaccines for Children Program
* VAERS
* VSD

Vaccines|

| Bacterial|

* Anthrax
* Brucellosis
* Cholera#
* Diphtheria#
* Hib#
* Leptospirosis
* Lyme disease‡
* Meningococcus#
* MeNZB
* Medicine:NmVac4-A/C/Y/W-135
* Pertussis#
* Plague
* Pneumococcal#
* PCV
* PPSV
* Q fever
* Tetanus#
* Tuberculosis
* BCG#
* Typhoid#
* Ty21a
* ViCPS
* Typhus
* combination: DTwP/DTaP

|

Viral|

* Adenovirus
* Flu#
* H1N1 (Pandemrix)
* LAIV
* Hantavirus
* Hepatitis A#
* Hepatitis B#
* Hepatitis E
* HPV
* Cervarix
* Gardasil
* Japanese encephalitis#
* Measles#
* Mumps#
* Medicine:Mumpsvax
* Polio#
* Sabin
* Salk
* Rabies#
* Rotavirus#
* Rubella#
* Smallpox
* Medicine:Dryvax
* Tick-borne encephalitis
* Varicella zoster
* chicken pox#
* Zoster vaccine
* Yellow fever#
* combination:
* MMR
* MMRV
* research:
* Chikungunya
* Cytomegalovirus
* Dengue
* Ebola
* Epstein–Barr virus
* Hepatitis C
* HIV

Protozoan|

* Malaria
* RTS,S
* research:
* Trypanosomiasis

Helminthiasis|

* research:
* Hookworm
* Schistosomiasis

Other|

* Androvax (androstenedione albumin)
* Cancer vaccines
* ALVAC-CEA
* BCG#
* Hepatitis B#
* HPV
* Cervarix
* Gardasil
* PROSTVAC
* NicVAX
* Ovandrotone albumin (Fecundin)
* TA-CD
* TA-NIC
* combination
* DTaP-IPV/Hib
* DTaP-IPV-HepB
* Hexavalent vaccine
* Pentavalent vaccine

Controversy|

* General
* MMR
* NCVIA
* Pox party
* Thiomersal
* Vaccines and SIDS
* Lancet MMR autism fraud
* Cedillo v. Secretary of Health and Human Services
* Alternative vaccination schedule

Related|

* Epidemiology
* Eradication of infectious diseases
* Every Child by Two
* List of vaccine topics

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

0.00

(0 votes)

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Pneumococcal_polysaccharide_vaccine&oldid=519441"
*[US]: United States
*[AU]: Australia
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template